Company news
Rocket Pharmaceuticals, Inc. news in 2023
Rocket Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.
Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors
December 11, 2023
Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
November 5, 2023
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
October 18, 2023
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
October 1, 2023
Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines Conference
September 25, 2023
Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock
September 12, 2023
Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease
September 11, 2023
Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress
August 9, 2023
Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
June 7, 2023
Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease
May 30, 2023
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency (PKD)
May 22, 2023
Rocket Pharmaceuticals Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
May 18, 2023
Rocket Pharmaceuticals Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
May 8, 2023
Rocket Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Progress
May 3, 2023
Rocket Pharmaceuticals to Participate in the Bank of America Securities 2023 Healthcare Conference
May 2, 2023
Rocket Pharmaceuticals Announces Leadership Expansion to Support Company on Evolution Towards Commercial Stage
April 3, 2023
Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference
February 28, 2023
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results
February 26, 2023
Rocket Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
February 8, 2023
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease
February 6, 2023
Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease
January 8, 2023
Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
January 2, 2023
Decks in 2023
- Corporate Update (September 2023)
Corporate update · 25 slides · Sep 12, 2023
- 41st Annual J.P. Morgan Healthcare Conference (January 2023)
Conference · 45 slides · Jan 9, 2023